PHARMACYTE BIOTECH, INC. Loss Contingency, Settlement Agreement, Consideration (Deprecated 2013-01-31)
PHARMACYTE BIOTECH, INC. (PMCB) had Loss Contingency, Settlement Agreement, Consideration (Deprecated 2013-01-31) of $1.98 million as of 2012-05-16, per its 10-Q filed 2013-03-26.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LossContingencySettlementAgreementConsideration1 · last filed 2013-03-26
- 2012-05-16: Loss Contingency, Settlement Agreement, Consideration (Deprecated 2013-01-31) $1.98M.
| Period end | Loss Contingency, Settlement Agreement, Consideration (Deprecated 2013-01-31) |
|---|---|
| 2012-05-16 | $1.98M 10-Q · filed 2013-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |